Interestingly, monomeric GLP-1R agonists, like semaglutide and liraglutide, as well as dual GLP-1R agonists like tirzepatide, have been FDA-approved for the treatment of T2DM and metabolic disorders, including chronic weight management in adults with obesity [32,33]. Here, GLP1R is linked to Obesity.